Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 4/20 | 0.46 |
| ▸ | ARG2 | P78540 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 11/20 | 0.42 |
| ▸ | GRM6 | O15303 | 6/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 6/20 | 0.42 |
| ▸ | GRM8 | O00222 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.41 |
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294440 | 1.00 | ARG1 (0.46) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8443472 | 1.00 | ARG1 (0.46) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL22415975 | 0.93 | GRM2 (0.41) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8440792 | 0.93 | GRM2 (0.41) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8438917 | 0.93 | GRM2 (0.41) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8443338 | 0.93 | GRM2 (0.41) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8441724 | 0.93 | GRM2 (0.41) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8438555 | 0.91 | GRM2 (0.40) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8442848 | 0.91 | GRM2 (0.40) | ARG1ARG2GRM2GRM6GRM3 | |
| SCHEMBL8441716 | 0.91 | GRM2 (0.40) | ARG1ARG2GRM2GRM6GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2353714-A1 | ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2011-08-10 | — | — | EP | disclosed |
| US-6958358-B2 | administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide | AMURA THERAPEUTICS LIMITED (GB) | 2005-10-25 | — | — | US | disclosed |
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| US-5959141-A | 1-amino-2-hydroxycycloalkanecarboxylic acid derivatives | SUNTORY LIMITED (JP) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | ARG1 558/4885ARG2 1320/4885GRM2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.